South Korea's Samsung Biologics Bids CHF1.5 Billion for Swiss Pharma Supplier Polypeptide

A staggering CHF 1.5 billion cash offer has just landed on the desk of Polypeptide, signaling a massive consolidation in the Swiss pharmaceutical sector. South Korean giant Samsung Biologics is moving with aggressive precision, offering CHF 44.31 per share—a dramatic 40% premium over the company's valuation before takeover whispers began in April. This is not just a purchase; it is a strategic conquest. The board of directors has already signaled its support, and with Draupnir Holding ready to offload its 56% stake, the path to a total takeover looks increasingly inevitable. This deal demands a two-thirds acceptance rate to proceed, but with such a heavy premium on the table, investors are likely to scramble for the exit. The sheer scale of this bid underscores the intense appetite for Swiss precision engineering in the global biopharma race. As the ink dries on the proposal, the Swiss Stock Exchange is bracing for a seismic shift in its pharmaceutical landscape.

Nearly 1,500 specialized employees across six global sites form the backbone of Polypeptide’s operations, making it a crown jewel of Swiss manufacturing. The company produces peptides—short protein building blocks that serve as the critical active ingredients in modern treatments for metabolic and hormonal disorders. These are the high-tech 'bricks' of the pharmaceutical world, and Polypeptide has been refining their production since its roots in 1952. By acquiring this expertise, Samsung Biologics isn't just buying a factory; it is securing a legacy of innovation that spans from Sweden to the United States and India. The demand for these specialized proteins is skyrocketing as global healthcare shifts toward personalized medicine and complex biologics. For Samsung, this acquisition provides an immediate, high-capacity bridge into the European market, bypassing years of infrastructure development. The Swiss firm’s ability to manufacture at scale while maintaining rigorous quality standards makes it an indispensable partner in the global supply chain.

Turnover soared by an incredible 42% to €236.6 million in the first half of 2026 alone, proving that Polypeptide is a company on a vertical trajectory. After grappling with losses in the previous year, the manufacturer has staged a spectacular return to profitability, prompting leadership to raise its full-year outlook. This financial resurgence likely accelerated Samsung’s decision to strike now before the valuation climbed even higher. The company now expects stronger turnover growth and a significantly higher operating profit margin for the remainder of 2026. This is a classic turnaround story fueled by the global explosion in peptide-based therapies. While many industrial sectors face stagnation, Polypeptide is outperforming expectations, demonstrating the resilience of the Swiss pharma-supplier model. The 2021 listing on the Swiss Stock Exchange was just the beginning; this potential acquisition represents the ultimate validation of the company's aggressive growth strategy and operational efficiency.

The Swiss pharmaceutical industry remains a global heavyweight, but the rise of Asian titans like Samsung Biologics is fundamentally shaking the status quo. This CHF 1.5 billion bid highlights a critical trend: Swiss innovation is increasingly being targeted by cash-rich foreign entities looking to dominate the life sciences sector. While the influx of Korean capital brings stability and expansion potential, it also raises questions about the long-term autonomy of the Swiss 'Pharma Valley.' As new players enter the arena, local giants must confront a reality where competition for talent and manufacturing capacity is no longer just regional, but fiercely global. The Swiss economy relies on these high-value exporters, and the transition of Polypeptide from a Swiss-listed entity to a subsidiary of a South Korean conglomerate marks a significant chapter in the nation's industrial history. Looking ahead, this deal may trigger a domino effect, as other international manufacturers look to Switzerland to secure their own supply chains in an increasingly volatile global market.